Comparative Pharmacology
Head-to-head clinical analysis: FLUOXETINE POSTPARTUM SAFETY versus PEXEVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOXETINE POSTPARTUM SAFETY versus PEXEVA.
Fluoxetine-Safety-Postpartum vs PEXEVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
None Documented
None Documented
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Category A/B
Category C
SSRI Antidepressant
SSRI Antidepressant